Skip to content

Assessment of Biological, Biometrological Parameters and Consumer Needs in Adult Subjects with Acne

Knowledge and Exploratory Study to Better Understand Face Acne Pathophysiology and Acne Lesion Severity by Multi-omic Approaches, Biometrological Analysis and Consumer Needs

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06841393
Enrollment
50
Registered
2025-02-24
Start date
2023-10-16
Completion date
2024-01-17
Last updated
2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne, Healthy

Brief summary

Acne vulgaris (acne) is a chronic inflammatory pathology of the pilosebaceous unit. Its prevalence is about 85% of teenagers and is constantly increasing in adults, especially women. Acne is a multifactorial disease involving abnormalities in follicular keratinization, sebum production, skin microbiota and inflammation. The early stage of acne is characterized by the presence of primary retentional lesions: the open comedones (or blackheads) and closed comedones (or whitehead). These retentional lesions can progress to highly inflammatory lesions: superficial inflammatory lesions (papules and pustules) and in some cases in deep inflammatory lesions (nodules). Finally, acne lesions can lead to the development of superficial post inflammatory erythema or hyperpigmentation, resulting in emotional distress and a poorer quality of life. Currently, a better understanding of the switch from healthy to acne-prone skin, but also of the transition from retentional lesions to more severe inflammatory lesions, seems essential to propose adapted and specific treatments. The aim of this study is to better understand acne pathophysiology of the face by a multi-omic approaches, biometrological analysis and consumer needs collection to bring information, in the same study on the local ecosystem of non-lesional areas, retentional lesional areas and inflammatory lesional areas of adult acne prone skin, compared to acne free face.

Interventions

Measurements will be taken from the face: * For acne group: inflammatory lesional area and non-lesional area * For control group: non-lesional area

OTHERBiological sampling

Samples will be taken from the face: * For acne group: inflammatory lesional area, non-lesional area and retentional area * For control group: non-lesional area

Only for acne group: acne scores will be evaluated on the face by the investigator

OTHERQuestionnaire

Only for acne group: consumers' perception

Sponsors

Pierre Fabre Dermo Cosmetique
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

Inlcusion criteria: Criteria related to the population: * Subject aged between 18 and 30 years included * For women of childbearing potential: use of an effective method of contraception, as assessed by the investigator, introduced and unchanged for at least 3 months before inclusion in the study Criteria related to diseases: Specific for acne group: • Subject with acne lesions on the face, with a Global Acne Evaluation (GEA) score evaluated on the face of 2 (mild) or 3 (moderate) assessed by the investigator on a 5-point scale (0, 1, 2, 3, 4, 5 with 0 = clear - no lesions and 5 = very severe) Non-inclusion criteria: Criteria related to the population: * For women of childbearing potential: pregnant or breastfeeding * Subject having received on face artificial UV exposure, excessive or prolonged exposure to natural sunlight within 4 weeks before the inclusion visit * Subject with facial hair liable to interfere with the study assessments Criteria related to the disease: * Clinical signs of hormone dysfunction or hyperandrogenism * Severe form of acne (acne conglobata, acne fulminans or nodulocystic acne) or acneiform eruptions, in the investigator's opinion * Sunburn on the face due to excessive UV exposure Criteria related to skin condition: • Subject having any other dermatologic condition than acne, or characteristics (like tattoo) on the face liable to interfere with the study assessments Specific for control group: * Subject with significant acne lesions according to investigator assessment * Subject having any inflammatory face dermatosis Criteria related to treatments and/or products: * Any surgery, chemical or physical treatment on the face in the 12 months before the inclusion visit * Systemic isotretinoin treatment taken in the 6 months prior before the inclusion visit * Systemic acne treatment taken in the 3 months before the inclusion visit * Probiotics taken orally in the month before the inclusion visit * Topical acne treatment applied to the face in the month before the inclusion visit * Topical or Systemic Non-Steroidal Anti-Inflammatory (NSAI), corticosteroids, taken or applied to the face in the 2 weeks before the inclusion visit * Skincare product for acne liable to interfere with the study according to investigator's assessment applied to the face in the 2 weeks before the inclusion visit

Design outcomes

Primary

MeasureTime frameDescription
Cutaneous pH measurementbaseline (Visit 1- Day 1)by pH - pHmeter
Sebum quantificationbaseline (Visit 1- Day 1)by Lipidic Index (LI) - Sebumeter®
Cutaneous barrier integritybaseline (Visit 1- Day 1)by Trans-Epidermal Water Loss (TEWL) - Aquaflux®
Epigenetic analysis by sampling method (urine)baseline (Visit 1- Day 1)
Microbiota profile by sampling method (swabs)baseline (Visit 1- Day 1)By non-targeting metagenomics
Microbiota profile by sampling method (extracted comedones)baseline (Visit 1- Day 1)for acne group only
Metabolomic profile by sampling method (swabs)baseline (Visit 1- Day 1)By metabolomic analysis
Metabolomic profile by sampling method (extracted comedones)baseline (Visit 1- Day 1)for acne group only
Lipidomic profile by mass spectroscopy (in-vivo measurements)baseline (Visit 1- Day 1)Each characteristic peak corresponding to specific lipid will be quantified by its mass intensity
Lipidomic profile by sampling method (scotch)baseline (Visit 1- Day 1)By lipidomic analysis
Lipidomic profile by sampling method (extracted comedones)baseline (Visit 1- Day 1)for acne group only
Acne severity on the facebaseline (Visit 1- Day 1)using Global Acne Evaluation (GEA) scale on a 6-point scale (0, 1, 2, 3, 4, 5 with 0 = clear - no lesions and 5 = very severe) in acne group only
Lesions quantificationbaseline (Visit 1- Day 1)by the number of inflammatory lesions (papules and/or pustules) in acne group
Consumers' perceptionbaseline (Visit 1- Day 1)by a questionnaire about acne skin, skincare routine, needs and expectations in terms of facial care in acne group

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026